Published : Oct-2021
No. of Pages : 131
1 Head and Neck Squamous Cell Carcinoma: Executive Summary
1.1 The Head and Neck Squamous Cell Carcinoma Market Will Grow to $5.2B in 2030
1.2 Merck & Co. Expected to Maintain Its Market-Leading Position
1.3 Extending Overall Survival Remains a Major Unmet Need
1.4 Immune Checkpoint Inhibitors Expected to Launch in Locally Advanced and Recurrent/Metastatic Settings
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.5 Epidemiological Forecast for HNC (2020-2030)
4.6 Discussion
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Key Opinion Leader Insights on Disease Management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Urban China
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix
List of Tables
Table 1: Head and Neck Squamous Cell Carcinoma: Key Metrics in the 8MM
Table 2: ICD-10 Codes Used to Classify HNC
Table 3: TNM Classification of Cancers of the Oral Cavity (Including Mucosa of the Lip)
Table 4: TNM Classification of Cancers of the Oropharynx (p16-) and Hypopharynx
Table 5: TNM Classification of Cancers of the Oropharynx - HPV Mediated (p16+)
Table 6: TNM Classification of Cancers of the Larynx
Table 7: TNM Classification of Cancers of the Nasal Cavity and Paranasal Sinuses
Table 8: TNM Classification of Cancers of the Nasopharynx
Table 9: Stage Grouping for Cancers of the Oral Cavity (Including Mucosa of the Lip)
Table 10: Stage Grouping for Cancers of the Larynx
Table 11: Stage Grouping for Cancers of the Oropharynx (p16+)
Table 12: Stage Grouping for Cancers of the Oropharynx (p16-) and Hypopharynx
Table 13: Stage Grouping for Cancers of the Nasopharynx
Table 14: Risk Factors and Comorbid Conditions Associated with HNCs
Figure 15: 8MM, Diagnosed Incidence of HNC, Men and Women (Cases per 100,000 Population), Ages ?18 Years, 2020
Table 16: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ?18 Years, N, 2020
Table 17: 8MM, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ?18 Years, N, 2020
Table 18: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ?18 Years, N, 2020
Table 19: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ?18 Years, N, 2020
Table 20: Treatment Guidelines for HNSCC Across the 8MM
Table 21: Top 10 Deals by Value, 2018-2020
Table 22: HNSCC Market - Global Drivers and Barriers, 2020-2030
Table 23: Key Events Impacting Sales for HNSCC in the US, 2020-2030
Table 24: HNSCC Market - Drivers and Barriers in the US, 2020-2030
Table 25: Key Events Impacting Sales for HNSCC in the 5EU, 2020-2030
Table 26: HNSCC Market - Drivers and Barriers in the 5EU, 2020-2030
Table 27: Key Events Impacting Sales for HNSCC in Japan, 2020-2030
Table 28: HNSCC Market - Drivers and Barriers in Japan, 2020-2030
Table 29: Key Events Impacting Sales for HNSCC in Urban China, 2020-2030
Table 30: HNSCC Market - Drivers and Barriers in Urban China, 2020-2030
Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for HNSCC in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in HNSCC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of HNSCC During the Forecast Period in the Locally Advanced Setting
Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of HNSCC During the Forecast Period in the Recurrent/Metastatic Setting
Figure 5: Common Anatomical Sites of HNSCC
Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10); Nasopharynx Cancer (ICD-10 = C11); Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 8: 8MM, Sources Used, Five-Year Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 9: 8MM, Sources Used to Forecast the Risk Factors and Histology Distribution Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 10: 8MM, Sources Used to Forecast the Stage at Diagnosis Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Oropharynx Cancer, Nasopharynx Cancer, and Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
Figure 11: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 13: 8MM, Diagnosed Incident Cases of Oropharynx Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 15: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Age, N, Both Sexes, 2020
Figure 16: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Sex, N, Ages ?18 Years, 2020
Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 18: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 19: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Age, N, Both Sexes, 2020
Figure 20: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Sex, N, Ages ?18 Years, 2020
Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages ?18 Years, 2020
Figure 22: Treatment Algorithm in HNSCC: Oral Cavity (Including Mucosa of the Lip), Pharynx, Larynx, Salivary Glands, and Paranasal Sinuses
Figure 23: Treatment Algorithm in HNSCC: Nasopharynx
Figure 24: Unmet Needs and Opportunities in HNSCC
Figure 25: Overview of the Development Pipeline in HNSCC
Figure 26: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for HNSCC in the 8MM During the Forecast Period
Figure 27: Competitive Assessment of Key Pipeline Products - LA-HNSCC
Figure 28: Competitive Assessment of Key Pipeline Products - R/M-HNSCC
Figure 29: Analysis of the Company Portfolio Gap in HNSCC During the Forecast Period
Figure 30: Global (8MM) Sales Forecast by Country for HNSCC in 2020 and 2030
Figure 31: Sales Forecast by Class for HNSCC in the US in 2020 and 2030
Figure 32: Sales Forecast by Class for HNSCC in the 5EU in 2020 and 2030
Figure 33: Sales Forecast by Class for HNSCC in Japan in 2020 and 2030
Figure 34: Sales Forecast by Class for HNSCC in Urban China in 2020 and 2030
